President Trump vs. Drug Prices: What This Means for Israeli Pharma?

The US President is demanding immediate price cuts from pharmaceutical companies – and the impact is already being felt across global markets.
Attorneys Yifat Tsafrir  and Lana Tavor analyze in an article published on Calcalist how this will affect Israeli companies and identify the new opportunities emerging from these changes.
Key challenges: Declining profitability and shifts in funding strategies
Key opportunities: Direct-to-consumer sales models and attractive M&A transactions
Read the full analysis below 👇
https://did.li/FtKZH